trending Market Intelligence /marketintelligence/en/news-insights/trending/5ZgW1ivYGWLTMkrjafRVhQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck & Co. to acquire animal tracking company Antelliq for €2.1B

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merck & Co. to acquire animal tracking company Antelliq for €2.1B

Merck & Co. Inc. agreed to acquire all outstanding shares of privately held animal identification company Antelliq for a cash payment of about €2.1 billion.

The Kenilworth, N.J.-based drugmaker is acquiring Antelliq from funds advised by BC Partners, a London-based private equity firm. Antelliq will be a separately operated unit within Merck's animal health division following the deal.

Merck will also assume Antelliq's debt of €1.15 billion, which it plans to repay shortly after deal closing.

Antelliq develops digital products for monitoring and tracking the health and well-being of livestock and pets. The France-based company had sales of €360 million in the year ending Sept. 30.

The acquisition complements Merck's animal health portfolio of pharmaceuticals, vaccines and services, Merck CEO Kenneth Frazier said in a news release.

The deal is expected to close in the second quarter of 2019 and is subject to certain conditions, including clearance from antitrust and competition authorities.

Merck was represented by Barclays and Centerview Partners in the acquisition, while Antelliq was represented by Goldman Sachs International and Rothschild & Co.

During Merck's first-quarter earnings call in May, Frazier said the drugmaker is sticking to its animal health division, rejecting suggestions that a spinoff was part of its strategy. The CEO added that the business provides a counterweight to a perceived overreliance on its lead cancer product, Keytruda.